Alterity Therapeutics Limited (PBN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Alterity Therapeutics Limited (PBN) has a cash flow conversion efficiency ratio of -0.222x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-5.06 Million ≈ $-5.91 Million USD) by net assets (€22.81 Million ≈ $26.67 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Alterity Therapeutics Limited (PBN) defensive interval to measure how many days the company can operate on defensive assets alone.
Alterity Therapeutics Limited - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Alterity Therapeutics Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Alterity Therapeutics Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Alterity Therapeutics Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Seosan Corporation
KQ:079650
|
-0.003x |
|
abrdn Asia Pacific Income Fund VCC
TO:FAP
|
-0.049x |
|
Huikwang
TWO:6508
|
0.041x |
|
Victek Co. Ltd
KQ:065450
|
-0.090x |
|
Futebol Clube do Porto - Futebol S.A.D.
LS:FCP
|
-0.035x |
|
Sparebank 68 Grader Nord
OL:SB68
|
N/A |
|
DY Corporation
KO:013570
|
0.007x |
|
Finetek Co. Ltd
KQ:131760
|
-0.071x |
Annual Cash Flow Conversion Efficiency for Alterity Therapeutics Limited (2014–2025)
The table below shows the annual cash flow conversion efficiency of Alterity Therapeutics Limited from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Alterity Therapeutics Limited.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | €42.40 Million ≈ $49.57 Million |
€-11.45 Million ≈ $-13.39 Million |
-0.270x | +70.44% |
| 2024-06-30 | €13.80 Million ≈ $16.13 Million |
€-12.61 Million ≈ $-14.74 Million |
-0.914x | -4.02% |
| 2023-06-30 | €22.81 Million ≈ $26.67 Million |
€-20.04 Million ≈ $-23.42 Million |
-0.878x | -152.49% |
| 2022-06-30 | €35.47 Million ≈ $41.47 Million |
€-12.34 Million ≈ $-14.42 Million |
-0.348x | +38.84% |
| 2021-06-30 | €30.47 Million ≈ $35.62 Million |
€-17.33 Million ≈ $-20.26 Million |
-0.569x | +56.88% |
| 2020-06-30 | €7.15 Million ≈ $8.36 Million |
€-9.43 Million ≈ $-11.03 Million |
-1.319x | -56.46% |
| 2019-06-30 | €16.55 Million ≈ $19.35 Million |
€-13.95 Million ≈ $-16.31 Million |
-0.843x | -117.06% |
| 2018-06-30 | €16.08 Million ≈ $18.80 Million |
€-6.25 Million ≈ $-7.30 Million |
-0.388x | -56.86% |
| 2017-06-30 | €23.69 Million ≈ $27.70 Million |
€-5.87 Million ≈ $-6.86 Million |
-0.248x | -4.68% |
| 2016-06-30 | €31.37 Million ≈ $36.67 Million |
€-7.42 Million ≈ $-8.67 Million |
-0.237x | +14.91% |
| 2015-06-30 | €39.11 Million ≈ $45.73 Million |
€-10.87 Million ≈ $-12.71 Million |
-0.278x | +22.62% |
| 2014-06-30 | €37.69 Million ≈ $44.06 Million |
€-13.54 Million ≈ $-15.83 Million |
-0.359x | -- |
About Alterity Therapeutics Limited
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II… Read more